INTRODUCTION {#s1}
============

Cancer is a major public health problem worldwide, with an estimated 14.1 million new cancer cases and 8.2 million deaths in 2012 \[[@R1]\]. Carcinogenesis is a complex process, influenced by various genetic and environmental factors, such as smoking, poor diet, physical inactivity, reproductive changes and the growth and aging of the population \[[@R1], [@R2]\]. Telomeres, composed of the TTAGGG repeat sequence, are special chromatin structures located at each end of a chromosome. Telomeres maintain chromosomal integrity by protecting chromosome ends from DNA damage and end-to-end fusions \[[@R3]\]. Abnormally short telomeres may cause chromosomal instability, and consequentially contribute to cancer development. Telomerase (also known as terminal transferase), a reverse transcriptase enzyme, extends the 3′ end of chromosomal DNA by catalyzing the telomere synthesis reaction. Defects in telomerase activity have been observed in many human tumor cells, and telomere length was inversely associated with cancer incidence and mortality \[[@R4]\]. Telomerase reverse transcriptase (TERT), the telomerase catalytic subunit, maintains telomere stability \[[@R5]\]. In a previous genome-wide association study (GWAS), Shete, *et al*. discovered that certain *TERT* gene variants increase glioma susceptibility \[[@R6]\]. Since then, *TERT* variants have been associated with various cancers, including breast, lung, colorectal, ovarian, prostate, and gastric cancers \[[@R7], [@R8]\].

The *TERT* gene is located in 5p15.33. The rs2736100 T \> G polymorphism in the second intron of the *TERT* gene has been associated with shortened telomere length in gastric cancer \[[@R9]\]. The association of this SNP with cancer susceptibility has been extensively explored, although the findings are as yet inconclusive. Several meta-analyses published in 2014 associated the *TERT* rs2736100 polymorphism with increased glioma and lung cancer susceptibility \[[@R10]--[@R14]\]. In 2012, Zou, *et al*. observed an association between this polymorphism and overall cancer risk \[[@R15]\], although their meta-analysis involved only 11 articles. However, between 2015 and 2016, more than 27 studies were published with large sample sizes \[[@R9], [@R16]--[@R37]\]. Thus, we performed an updated meta-analysis to more precisely assess the *TERT* rs2736100 polymorphism-cancer association, including 72 studies derived from 61 articles with 269,720 total subjects \[[@R6], [@R9], [@R16]--[@R74]\].

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

We initially identified 432 records from the PubMed and EMBASE databases (Figure [1](#F1){ref-type="fig"}). After screening titles and abstracts, 268 articles were excluded and the full texts of the remaining 164 articles were further assessed. Articles were excluded for the following reasons: irrelevant association (87 articles), meta-analysis (7), and lacking sufficient raw data for further evaluation (12). Three additional articles were identified by manually screening the references of relevant articles. Finally, 72 studies extracted from 61 articles met our study inclusion criteria and were included in the current meta-analysis \[[@R6], [@R9], [@R16]--[@R74]\].

![Flowchart of articles included in our meta-analysis](oncotarget-08-38693-g001){#F1}

In most of the included studies, the *TERT* rs2736100 polymorphism genotypic distribution followed Hardy-Weinberg equilibrium (HWE) in controls, except for seven studies \[[@R6], [@R28], [@R43], [@R51], [@R63], [@R66], [@R72]\]. Since the genotype distributions of other polymorphisms were in compliance with HWE in these seven studies, we included these studies in the meta-analysis. In total, 72 studies with 108,248 cases and 161,472 controls were included in our pooled analysis. Studies were conducted on various cancer types, including lung (28 studies), glioma (5), colorectal (4), bladder (4), myeloproliferative neoplasms (MPN) (4), gastric (3), acute myeloid leukemia (AML) (2), breast (2), melanoma (2), and thyroid (2). The remaining 16 studies focused on different types of cancer, with one study for each type of cancer, and were grouped together as "other cancer" in our analyses. There were 37 studies conducted in Asians and 35 in Caucasians. Twenty-three studies included fewer than 500 controls, and 49 had 500 or more controls. Sixteen studies were categorized as low quality and 56 were high quality. The main characteristics of all the studies are summarized in Table [1](#T1){ref-type="table"}.

###### The main characteristics of all the studies included in the meta-analysis

  Surname            Year   Country       Ethnicity   Cancer type         Cases   Controls   HWE       Score                                                
  ------------------ ------ ------------- ----------- ------------------- ------- ---------- --------- --------- ------- ------ --------- --------- ------- ----
  Zhou               2016   China         Asian       ESCC                588     165        275       148       600     215    287       108       0.472   11
  Zhang              2016   China         Asian       NC                  855     265        428       162       1036    365    516       155       0.211   13
  Yuan               2016   China         Asian       UTUC                212     83         81        48        289     86     144       59        0.928   10
  Xing               2016   China         Asian       Lung cancer         418     216        164       38        410     268    124       18        0.452   10
  Wang               2016   China         Asian       Lung cancer         500     131        257       112       500     178    242       80        0.881   11
  Trifa              2016   Romania       Caucasian   MPN                 529     76         255       198       433     124    213       96        0.802   13
  Krahling 1         2016   Hungary       Caucasian   PMN                 584     77         282       225       400     111    188       101       0.235   8
  Krahling 2         2016   Hungary       Caucasian   CML                 86      25         43        18        400     111    188       101       0.235   8
  Krahling 3         2016   Hungary       Caucasian   AML                 308     71         153       84        400     111    188       101       0.235   7
  Gong               2016   China         Asian       Thyroid cancer      452     142        214       96        452     156    222       74        0.738   11
  Ge                 2016   China         Asian       Thyroid cancer      2300    644        1093      563       2300    875    1056      369       0.093   12
  Dahlstrom 1        2016   Sweden        Caucasian   MPN                 126     15         64        47        756     167    377       212       0.980   9
  Dahlstrom 2        2016   China         Asian       MPN                 101     17         52        32        101     33     50        18        0.722   8
  Bayram             2016   Turkey        Caucasian   Gastric cancer      104     16         44        44        209     61     82        66        0.002   9
  Li                 2016   China         Asian       Lung cancer         391     109        201       81        337     117    159       61        0.587   9
  Shiraishi          2016   Japan         Asian       Lung cancer         6830    2057       3386      1387      15155   5723   7133      2299      0.323   13
  Wei                2015   China         Asian       Lung cancer         702     190        353       159       2520    814    1269      437       0.130   12
  Shadrina 1         2015   Russia        Caucasian   Prostate cancer     360     102        183       75        358     105    165       88        0.150   11
  Shadrina 2         2015   Russia        Caucasian   Breast cancer       642     192        310       140       523     132    280       111       0.097   12
  Mosrati            2015   Sweden        Caucasian   AML                 226     48         113       65        788     201    406       181       0.382   10
  Liu                2015   China         Asian       Lung cancer         288     72         139       77        317     92     173       52        0.052   9
  Du                 2015   China         Asian       Gastric cancer      1105    360        557       188       994     346    464       184       0.197   11
  de Martino         2015   Austria       Caucasian   RCC                 241     61         120       60        375     97     181       97        0.502   10
  Choi               2015   South Korea   Asian       Gastric cancer      243     34         107       102       246     38     122       86        0.625   8
  Campa              2015   Germany       Caucasian   Pancreatic cancer   1724    445        861       418       3512    817    1763      932       0.764   13
  Campa              2015   Germany       Caucasian   Multiple myeloma    2052    535        958       559       2633    634    1285      714       0.237   13
  Adel Fahmideh      2015   Sweden        Caucasian   Brain tumor         240     61         103       76        478     109    256       113       0.120   12
  Yin                2014   China         Asian       Lung cancer         524     139        273       112       524     186    255       83        0.777   11
  Wang               2014   China         Asian       Lung cancer         1552    455        764       333       1605    549    780       276       0.971   12
  Liorca-Cardenosa   2014   Spain         Caucasian   Melanoma            629     146        297       186       371     94     177       100       0.380   9
  Zhao               2013   China         Asian       Lung cancer         1759    596        1163^a^   1163^a^   1804    674    1130^a^   1130^a^   /       9
  Sheng              2013   China         Asian       ALL                 569     178        270       121       656     233    323       100       0.490   13
  Pellatt            2013   USA           Caucasian   Breast cancer       3698    1450       1934      314       3534    1179   1674      681       0.047   11
  Pellatt 1          2013   USA           Caucasian   Colon cancer        1555    410        798       347       1956    493    956       507       0.321   12
  Pellatt 2          2013   USA           Caucasian   Rectal cancer       754     214        356       184       959     270    465       224       0.386   12
  Myneni             2013   China         Asian       Lung cancer         352     122        141       89        447     157    212       78        0.659   8
  Ma                 2013   China         Asian       Bladder Cancer      177     55         87        35        961     340    455       166       0.516   10
  Lan                2013   China         Asian       Lung cancer         193     43         109       41        197     70     103       24        0.137   9
  Wang               2012   China         Asian       Cervical Cancer     1010    322        462       226       1006    352    480       174       0.637   11
  Rajaraman ^b^      2012   USA           Caucasian   Glioma              1854    /          /         /         4949    /      /         /         /       12
  Kinnersley         2012   UK            Caucasian   Colorectal cancer   16039   4191       8105      3743      16430   4090   8082      4258      0.039   12
  Ito                2012   Japan         Asian       Lung cancer         716     248        340       128       716     279    329       108       0.496   12
  Hofer              2012   Austria       Caucasian   Colorectal cancer   137     38         68        31        1705    458    859       388       0.700   11
  Chen               2012   China         Asian       Lung cancer         196     45         101       50        229     69     112       48        0.838   10
  Shiraishi          2012   Japan         Asian       Lung cancer         4648    1386       2265      997       12364   4650   5856      1858      0.838   13
  Bae                2012   Korea         Asian       Lung cancer         1094    402        501       191       1100    422    522       156       0.790   10
  Pande ^b^          2011   USA           Caucasian   Lung cancer         1681    /          /         /         1235    /      /         /         /       10
  Nan 1              2011   USA           Caucasian   Melanoma            210     55         91        64        831     215    399       217       0.252   11
  Nan 2              2011   USA           Caucasian   SCC                 277     57         125       95        831     215    399       217       0.252   11
  Nan 3              2011   USA           Caucasian   BCC                 274     68         116       90        831     215    399       217       0.252   11
  Kohno              2011   Japan         Asian       Lung cancer         377     142        175       53        325     116    165       39        0.090   9
  Hu                 2011   China         Asian       Lung cancer         8559    2393       4294      1872      9378    3231   4533      1614      0.724   13
  Ding               2011   China         Asian       HC                  1269    428        633       208       1322    449    651       222       0.591   12
  Chen               2011   China         Asian       Glioma              953     244        515       194       1036    334    542       160       0.014   10
  Jaworowsk 1        2011   Poland        Caucasian   Lung cancer         855     247        403       205       844     263    425       156       0.494   11
  Jaworowsk 2        2011   Poland        Caucasian   Bladder Cancer      431     134        216       81        439     134    226       79        0.335   10
  Jaworowsk 3        2011   Poland        Caucasian   Laryngeal cancer    413     124        211       78        406     130    199       77        0.956   10
  Gago-Dominguez 1   2011   USA           Caucasian   Bladder Cancer      471     86         239       146       547     127    262       158       0.361   11
  Gago-Dominguez 2   2011   USA           Asian       Bladder Cancer      499     141        260       98        525     174    274       77        0.064   10
  Wang               2010   UK            Caucasian   Lung cancer         239     42         115       82        553     136    259       158       0.146   8
  Turnbull           2010   UK            Caucasian   TGCT                1588    520        767       301       7683    1904   3718      2061      0.005   10
  Miki               2010   Japan         Asian       Lung cancer         2086    622        1048      416       1103    4093   5246      1695      0.835   13
  Kohno              2010   Japan         Asian       Lung cancer         1656    488        796       372       968     373    460       135       0.719   13
  Hsiung             2010   China         Asian       Lung cancer         2308    599        1187      522       2321    852    1132      337       0.211   12
  Yoon               2010   Korea         Asian       Lung cancer         1425    467        696       262       3011    1187   1405      419       0.921   11
  Truong 1           2010   France        Caucasian   Lung cancer         9126    1878       4526      2722      11812   2853   5817      3142      0.116   13
  Truong 2           2010   France        Asian       Lung cancer         1686    538        836       312       2101    775    1014      312       0.506   12
  Schoemaker         2010   UK            Caucasian   Glioma              216     30         114       72        241     54     127       60        0.397   9
  Shete              2009   USA           Caucasian   Glioma              4344    781        2213      1350      6457    1623   3122      1712      0.008   11
  Landi ^b^          2009   USA           Caucasian   Lung cancer         5739    /          /         /         5848    /      /         /         /       11
  Jin                2009   China         Asian       Lung cancer         1212    353        627       232       1339    450    658       231       0.719   13
  Wrensch            2009   USA           Caucasian   Glioma              691     95         354       242       3981    1021   1904      1056      0.006   12

Abbreviations: ESCC: esophageal squamous cell carcinoma; NC: nasopharyngeal carcinoma; UTUC: upper tract urothelial carcinomas; MPN: myeloproliferative neoplasms; CML: chronic myeloid leukemia; AML: acute myeloid leukemia; RCC: renal cell carcinoma; ALL: acute lymphoblastic leukemia; SCC: squamous cell carcinoma; BCC: basal cell carcinoma; HC: hepatocellular carcinoma; TGCT: testicular germ cell tumor; HWE: Hardy-Weinberg equilibrium

a: Number of cases and controls for TG and GG genotypers. b: The allele frequence in the three studies was provided to estimate the association under allele contrast model (G vs. T).

Meta-analysis results {#s2_2}
---------------------

Heterogeneity among studies was observed for all five genetic models. Consequently, the random effect model was applied to calculate odds ratios (ORs). Risk estimates indicated that the *TERT* rs2736100 polymorphism was associated with overall cancer risk via all five genetic models \[homozygous model (GG vs. TT): OR=1.39, 95% confidence interval (CI)=1.26--1.54, *P*\<0.001; heterozygous model (TG vs. TT): OR=1.16, 95% CI=1.11--1.23, *P*\<0.001; dominant model (TG + GG vs. TT): OR=1.23, 95% CI=1.15--1.31, *P*\<0.001; recessive model (GG vs. TG + TT): OR=1.25, 95% CI=1.16--1.35, *P*\<0.001; and allele contrast model (G vs. T): OR=1.17, 95% CI=1.12--1.23, *P*\<0.001 (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"})\]. The stratified analysis by cancer type associated the *TERT* rs2736100 polymorphism with lung cancer risk (homozygous model: OR=1.60, 95% CI=1.49--1.71, *P*\<0.001; heterozygous model: OR=1.25, 95% CI=1.20--1.31, *P*=0.008; dominant model: OR=1.33, 95% CI 1.26--1.39, *P*\<0.001; recessive model: OR=1.40, 95% CI=1.32--1.48, *P*\<0.001; and allele contrast model: OR=1.24, 95% CI=1.17--1.31, *P*\<0.001). This polymorphism was also associated with increased risk for thyroid cancer, bladder cancer, glioma, MPN and AML. Inversely, the *TERT* rs2736100 polymorphism was associated with decreased colorectal cancer risk (homozygous model: OR=0.86, 95% CI=0.82--0.91, *P*=0.512; dominant model: OR=0.94, 95% CI=0.90--0.98, *P*=0.970; recessive model: OR=0.88, 95% CI=0.82--0.96, *P*=0.279; and allele contrast model: OR=0.93, 95% CI=0.90--0.96, *P*=0.548). Stratified analysis was also performed by patient ethnicity, sample size of controls, and quality score. Elevated cancer risk was found among Asians in all five genetic models and among Caucasians under all five genetic models except for the recessive model. Our results also associated the *TERT* rs2736100 polymorphism with elevated overall cancer risk in all subgroups divided by sample size of controls and quality score in all the five genetic models.

![Forest plot of the association between the *TERT* rs2736100 polymorphism and overall cancer susceptibility in the allele contrast model](oncotarget-08-38693-g002){#F2}

###### Meta-analysis of *TERT* rs2736100 T\>G polymorphism on cancer risk

  Variables     Homozygous             Heterozygous   Recessive   Dominant               Allele                                                                                                                            
  ------------- ---------------------- -------------- ----------- ---------------------- --------- ------ ---------------------- --------- ------ ---------------------- --------- ------ ---------------------- --------- ------
  All           **1.39 (1.26-1.54)**   \<0.001        93.3        **1.16 (1.11-1.23)**   \<0.001   80.0   **1.25 (1.16-1.35)**   \<0.001   91.1   **1.23 (1.15-1.31)**   \<0.001   88.9   **1.17 (1.12-1.23)**   \<0.001   93.4
  Cancer type                                                                                                                                                                                                              
   Lung         **1.60 (1.49-1.71)**   \<0.001        65.7        **1.25 (1.20-1.31)**   0.008     45.5   **1.40 (1.32-1.48)**   \<0.001   61.2   **1.33 (1.26-1.39)**   \<0.001   58.6   **1.24 (1.17-1.31)**   \<0.001   89.4
   MPN          **3.17 (2.51-4.00)**   0.854          0.0         **2.03 (1.64-2.51)**   0.972     0.0    **1.89 (1.59-2.24)**   0.616     0.0    **2.40 (1.97-2.94)**   0.957     0.0    **1.74 (1.56-1.95)**   0.679     0.0
   AML          **1.40 (1.04-1.88)**   0.631          0.0         1.22 (0.94-1.59)       0.744     0.0    1.23 (0.97-1.56)       0.411     0.0    **1.28 (1.00-1.64)**   0.970     0.0    **1.18 (1.02-1.37)**   0.658     0.0
   Thyroid      **1.79 (1.25-2.56)**   0.076          68.3        1.26 (0.96-1.65)       0.085     66.2   **1.62 (1.37-1.92)**   0.266     19.3   **1.38 (1.02-1.88)**   0.041     76.0   **1.33 (1.08-1.64)**   0.040     76.4
   Gastric      1.39 (0.82-2.33)       0.028          72.1        1.22 (0.90-1.66)       0.204     37.2   1.19 (0.83-1.70)       0.044     68.1   1.31 (0.90-1.90)       0.085     59.4   1.22 (0.94-1.58)       0.023     73.5
   Breast       0.56 (0.25-1.28)       \<0.001        95.0        0.88 (0.73-1.07)       0.158     49.8   0.63 (0.24-1.64)       \<0.001   97.3   0.78 (0.71-0.85)       0.892     0.0    0.80 (0.61-1.04)       0.003     88.8
   Melanoma     1.18 (0.90-1.54)       0.890          0.0         1.00 (0.78-1.27)       0.444     0.0    1.18 (0.95-1.47)       0.700     0.0    1.06 (0.85-1.33)       0.570     0.0    1.09 (0.95-1.26)       0.922     0.0
   Colorectal   **0.86 (0.82-0.91)**   0.512          0.0         0.98 (0.93-1.03)       0.989     0.0    **0.88 (0.82-0.96)**   0.279     21.9   **0.94 (0.90-0.98)**   0.970     0.0    **0.93 (0.90-0.96)**   0.548     0.0
   Bladder      **1.31 (1.08-1.59)**   0.481          0.0         1.15 (0.98-1.34)       0.498     0.0    **1.18 (1.00-1.39)**   0.598     0.0    **1.19 (1.02-1.38)**   0.436     0.0    **1.13 (1.03-1.25)**   0.507     0.0
   Glioma       **1.89 (1.52-2.35)**   0.028          67.0        **1.55 (1.30-1.84)**   0.055     60.0   **1.35 (1.21-1.49)**   0.241     28.5   **1.65 (1.37-1.99)**   0.020     69.4   **1.33 (1.25-1.42)**   0.089     50.4
   Others       1.09 (0.89-1.32)       \<0.001        86.7        0.97 (0.88-1.07)       0.002     58.4   1.11 (0.95-1.29)       \<0.001   84.3   1.01 (0.89-1.13)       \<0.001   78.2   1.04 (0.94-1.15)       \<0.001   87.0
  Ethnicity                                                                                                                                                                                                                
   Asian        **1.56 (1.46-1.67)**   \<0.001        65.0        **1.22 (1.17-1.28)**   0.001     49.5   **1.39 (1.32-1.46)**   \<0.001   50.4   **1.30 (1.28-1.36)**   \<0.001   62.1   **1.25 (1.20-1.29)**   \<0.001   67.7
   Caucasian    **1.22 (1.04-1.44)**   \<0.001        94.4        **1.12 (1.02-1.22)**   \<0.001   83.6   1.11 (0.99-1.25)       \<0.001   92.5   **1.16 (1.04-1.29)**   \<0.001   90.7   **1.11 (1.03-1.19)**   \<0.001   94.2
  Sample Size                                                                                                                                                                                                              
   ≥ 500        **1.34 (1.19-1.51)**   \<0.001        95.1        **1.16 (1.09-1.23)**   \<0.001   83.7   **1.22 (1.11-1.33)**   \<0.001   93.6   **1.21 (1.13-1.30)**   \<0.001   91.5   **1.15 (1.09-1.22)**   \<0.001   95.1
   \<500        **1.52 (1.26-1.82)**   \<0.001        72.5        **1.19 (1.04-1.37)**   \<0.001   66.2   **1.34 (1.19-1.51)**   0.001     55.1   **1.29 (1.11-1.49)**   \<0.001   73.3   **1.23 (1.12-1.35)**   \<0.001   74.1
  Score                                                                                                                                                                                                                    
   High         **1.33 (1.18-1.48)**   \<0.001        94.5        **1.15 (1.09-1.21)**   \<0.001   82.7   **1.22 (1.12-1.33)**   \<0.001   92.8   **1.20 (1.12-1.28)**   \<0.001   90.8   **1.15 (1.09-1.21)**   \<0.001   94.5
   Low          **1.72 (1.40-2.10)**   0.001          60.5        **1.30 (1.10-1.54)**   0.003     57.0   **1.41 (1.26-1.59)**   0.154     27.4   **1.40 (1.20-1.63)**   \<0.001   65.7   **1.30 (1.18-1.43)**   \<0.001   60.5

Abbreviations: MPN, Myeloproliferative neoplasms; AML, Acute myeloid leukemia

Heterogeneity and sensitivity analyses {#s2_3}
--------------------------------------

Heterogeneity was detected amongst studies with respect to the association between the *TERT* rs2736100 polymorphism and overall cancer risk (homozygous model: *P*\<0.001; heterozygous model: *P*\<0.001; dominant model: *P*\<0.001; recessive model: *P*\<0.001; and allele contrast model: *P*\<0.001). Therefore, we used the random effects model to generate pooled ORs and 95% CIs. Sensitivity analyses indicated that no single study could change the between-study heterogeneity and the results of meta-analysis.

Publication bias {#s2_4}
----------------

The Begg\'s funnel plot and Egger\'s linear regression analysis did not reveal any evidence of publication bias in the meta-analysis (homozygous model: *P*=0.183; heterozygous model: *P*=0.805; dominant model: *P*=0.406; recessive model: *P*=0.085; and allele model: *P*=0.122; Figure [3](#F3){ref-type="fig"}).

![Funnel plot analysis to evaluate publication bias](oncotarget-08-38693-g003){#F3}

False positive report probability (FPRP) analyses {#s2_5}
-------------------------------------------------

We calculated FPRP values for associations between the *TERT* rs2736100 T\>G polymorphism and overall cancer risk using the five genetic models. FPRP values were all \<0.20, suggesting that these associations were noteworthy (Table [3](#T3){ref-type="table"}).

###### False-positive report probability values for associations between the *TERT* rs2736100 T\>G polymorphism and overall cancer risk

  Genetic models               OR (95% CI)        *P*       Power   Prior Probability                                   
  ---------------------------- ------------------ --------- ------- ------------------- ------- ------- ------- ------- -------
  Homozygous (GG vs. TT)       1.39 (1.26-1.54)   \<0.001   0.555   0.000               0.000   0.000   0.000   0.000   0.000
  Heterozygous (TG vs. TT)     1.16 (1.11-1.23)   \<0.001   0.872   0.000               0.000   0.000   0.001   0.008   0.073
  Recessive (GG vs. TG + TT)   1.25 (1.16-1.35)   \<0.001   0.841   0.000               0.000   0.000   0.000   0.000   0.002
  Dominant (TG +GG vs. TT)     1.23 (1.15-1.31)   \<0.001   0.957   0.000               0.000   0.000   0.000   0.000   0.000
  Allele (G vs. T)             1.17 (1.12-1.23)   \<0.001   0.839   0.000               0.000   0.000   0.000   0.000   0.000

DISCUSSION {#s3}
==========

Telomeres are special structures at the ends of eukaryotic chromosomes, and are responsible for protecting chromosomes from degradation, end-to-end fusion, and rearrangement \[[@R10]\]. Telomerase maintains proper telomere length by adding repetitive telomeric sequences to the 3′ ends of telomeres. Abnormal telomerase activity is implicated in the initiation and development of cancer and other age-associated diseases \[[@R75]\]. The TERT subunit of telomerase consists of three highly conserved domains: the RNA-binding domain (TRBD), the reverse transcriptase domain, and a carboxy-putative extension (CTE) proposed to constitute the putative thumb domain \[[@R75]\]. TERT is overexpressed in many human cancers \[[@R76]\]. The *TERT* rs2736100 polymorphism, localized in the second intron of the *TERT* gene, has been wildly studied with respect to cancer risk \[[@R7], [@R8]\]. However, the functional significance of the *TERT* rs2736100 polymorphism was not clear. Preliminary studies in gastric cancer suggested that this SNP is associated with decreased telomere length \[[@R9]\].

The present meta-analysis, comprising 108,248 cases and 161,472 controls, found that the *TERT* rs2736100 polymorphism increased overall cancer risk by 16--39%, suggesting that this SNP may contribute to carcinogenesis. A previous meta-analysis conducted by Zou, *et al*. in 2012 \[[@R15]\] also concluded that this polymorphism was associated with increased cancer risk. However, this analysis included only 11 case-control articles with 23,032 cases and 38,274 controls, which studied only lung cancer, glioma, and bladder cancer. Our stratified analysis by cancer type showed that the *TERT* rs2736100 polymorphism correlated with increased risk of lung cancer and glioma. Such associations were also observed in lung cancer- and glioma-specific meta-analyses published in 2014 \[[@R10]--[@R15], [@R77]\]. Between 2015 and 2016, at least 27 studies (6 studies on lung cancer) were published investigating the association between the *TERT* rs2736100 polymorphism and overall cancer susceptibility. To the best of our knowledge, ours is the largest meta-analysis of this association, with the strongest statistical power. Apart from lung cancer, glioma, and bladder cancer, our meta-analysis also investigated the association between the *TERT* rs2736100 polymorphism and risk of colorectal cancer (4 studies), MPN (4), gastric cancer (3), AML (2), breast cancer (2), melanoma (2), and thyroid cancer (2) as well as "other cancers" (16). We observed that this polymorphism was associated with decreased colorectal cancer risk. Since only four colorectal cancer studies were included in our meta-analysis, such an association might be a false positive, and validation will require further study.

The current meta-analysis had several limitations. First, there were substantial heterogeneities in the pooled study investigating the association between the *TERT* rs2736100 polymorphism and overall cancer risk. We reduced the degree of heterogeneity through stratified analyses by cancer type, patient ethnicity, sample size, and study quality score. Some cross-study heterogeneity might be attributed to differences among ethnic groups \[[@R78]\]. However, other sources of heterogeneity were not identified, such as control sources and genotyping methods. Second, the studies in this meta-analysis focused on Asian and Caucasian populations only, so we may not have had sufficient statistical power to evaluate associations based on ethnicity. Third, our results were based on unadjusted ORs due to the unavailability of confounding factor information for cases and controls (e.g., age, sex, smoking status, drinking status, and environmental exposure). Finally, lacking the original data from eligible studies limited our ability to explore gene-environment interactions.

In conclusion, our meta-analysis indicated that the *TERT* rs2736100 polymorphism was associated with increased overall cancer risk, especially lung cancer risk. Larger studies involving patients of different ethnicities are needed to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Identification of eligible studies {#s4_1}
----------------------------------

A comprehensive literature search of the PubMed and EMBASE databases was performed up to November 1, 2016. To find all eligible case-control studies that assessed the association between the *TERT* rs2736100 polymorphism and cancer risk, we used the following keywords: "TERT or telomerase reverse transcriptase", "polymorphism or variant", and "cancer or tumor or neoplasm or carcinoma". We also evaluated additional studies by manually screening the references of both primary articles and reviews.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Eligible studies included in our analysis met the following criteria: (i) the *TERT* rs2736100 polymorphism-cancer risk association was assessed; (ii) case-control studies or cohort studies; (iii) sufficient data to calculate an OR with 95% CI; (iv) studies in English. Exclusion criteria were as follows: (i) case only studies; (ii) overlapping publications; (iii) abstract, case report, editorial comment, and review. Studies that deviated from HWE in controls were excluded, unless further evidence showed that another polymorphism was in HWE.

Data extraction {#s4_3}
---------------

Two investigators independently extracted available data from each eligible study. The following information was collected: first author\'s surname, year of publication, country of origin, patient ethnicity, cancer type, numbers of cases and controls, genotype counts of cases and controls, results of the HWE test, and quality scores (low quality studies with score ≤9, high quality studies with score \>9) \[[@R79]\]. Any disagreements were solved by discussion until a consensus was reached between the two investigators. If no consensus was reached, another investigator joined the discussion, and a final decision was made by a majority.

FPRP analysis {#s4_4}
-------------

FPRP values were applied to assess the statistical power of our significant findings \[[@R80], [@R81]\]. An FPRP value of 0.20 was set as the criterion for noteworthiness. A prior probability of 0.1 was assigned to detect an OR of 0.67/1.50 (protective/risk effects) for an association with genotypes under investigation.

Statistical analysis {#s4_5}
--------------------

HWE in control subjects was assessed by chi-squared test. The strength of association between the *TERT* rs2736100 polymorphism and cancer risk was estimated by calculating crude ORs and their 95% CIs using all five genetic models: homozygous (GG vs. TT), heterozygous (TG vs. TT), dominant (GG vs. TG + TT), and recessive (TG + GG vs. TT), as well as the allele contrast model (G vs. T). Q-test was used to quantify heterogeneity among all eligible studies, and *P*\>0.10 suggested a lack of heterogeneity among studies. Generally, the fixed effects model (Mantel--Haenszel method) or the random effects model (DerSimonian--Laird method) was employed in the absence (*P*≥0.10) or presence (*P*\<0.10) of heterogeneity, respectively \[[@R82]--[@R84]\]. Heterogeneity was also estimated using the I^2^ test \[[@R85]\]. Subgroup analyses were conducted by patient ethnicity, cancer type, and study sample size. The Begg\'s funnel plot and the Egger\'s linear regression test were used to evaluate publication bias \[[@R86]\]. All statistical analyses were performed using STATA version 12.0 software (STATA Corporation, College Station, TX). All statistical analyses were two-sided. P\<0.05 was considered statistically significant.
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